Vincenzo Formica1, Francesco Sera2, Chiara Cremolini3,4, Silvia Riondino1, Cristina Morelli1, Hendrik-Tobias Arkenau5, Mario Roselli1. 1. Medical Oncology Unit, Department of Systems Medicine, Tor Vergata University Hospital, Rome, Italy. 2. Department of Statistics, Computer Science and Applications "G Parenti", University of Florence, Florence, Italy. 3. Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy. 4. Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy. 5. Sarah Cannon Research Institute, Cancer Institute, University College London, London, UK.
Abstract
BACKGROUND: KRAS and BRAF mutations are well-established predictive and prognostic factors in metastatic colorectal cancer; however, their impact in the adjuvant setting has not yet been established. METHODS: We performed a meta-analysis of adjuvant phase III trials in patients with stage II and III colon cancer with available data on the impact of KRAS or BRAF mutations on both disease-free survival (DFS) and overall survival (OS). Trials were subgrouped based on whether adjustment for microsatellite instability (MSI) was performed and the subgroup effect was analyzed through a meta-regression. To increase the precision of the estimates, a joint DFS-OS (so-called "multivariate") meta-analysis was performed. All statistical tests were 2-sided. RESULTS: Nine trials were selected (QUASAR 2, PETACC-8, N0147, CALGB-89803, NSABP-C07, NSABP-C08, PETACC-3, QUASAR, MOSAIC) including a total of 10 893 patients. In the primary meta-analysis, KRAS mutation was associated with poor DFS (pooled hazard ratio [HR] = 1.36, 95% confidence interval [CI] = 1.15 to 1.61, P < .001) and OS (pooled HR = 1.27, 95% CI = 1.03 to 1.55, P = .03) and BRAF mutation was also associated with poor DFS (pooled HR = 1.33, 95% CI = 1.00 to 1.78, P = .05) and OS (pooled HR = 1.49, 95% CI = 1.31 to 1.70, P < .001). The effect of the mutations on outcome was enhanced in the MSI-adjusted subgroup for both the KRAS mutation (pooled HR for DFS = 1.43, 95% CI = 1.15 to 1.79, P = .001; and pooled HR for OS = 1.33, 95% CI = 1.03 to 1.71, P = .03) and the BRAF mutation (pooled HR for DFS = 1.59, 95% CI = 1.22 to 2.07, P = .001; and pooled HR for OS = 1.67, 95% CI = 1.37 to 2.04, P < .001). The interaction between BRAF and MSI adjustment was statistically significant for DFS (Pinteraction = .02). This interaction was even more pronounced in the DFS-OS multivariate meta-analysis. CONCLUSIONS: Both KRAS and BRAF mutations were statistically significantly associated with both DFS and OS, with the mutation effect being enhanced by MSI adjustment. Effective adjuvant treatment for microsatellite-stable BRAF or KRAS-mutated colon cancer represents an unmet clinical need, and exploring the use of recently available BRAF and KRAS inhibitors in this setting would be highly desirable.
BACKGROUND: KRAS and BRAF mutations are well-established predictive and prognostic factors in metastatic colorectal cancer; however, their impact in the adjuvant setting has not yet been established. METHODS: We performed a meta-analysis of adjuvant phase III trials in patients with stage II and III colon cancer with available data on the impact of KRAS or BRAF mutations on both disease-free survival (DFS) and overall survival (OS). Trials were subgrouped based on whether adjustment for microsatellite instability (MSI) was performed and the subgroup effect was analyzed through a meta-regression. To increase the precision of the estimates, a joint DFS-OS (so-called "multivariate") meta-analysis was performed. All statistical tests were 2-sided. RESULTS: Nine trials were selected (QUASAR 2, PETACC-8, N0147, CALGB-89803, NSABP-C07, NSABP-C08, PETACC-3, QUASAR, MOSAIC) including a total of 10 893 patients. In the primary meta-analysis, KRAS mutation was associated with poor DFS (pooled hazard ratio [HR] = 1.36, 95% confidence interval [CI] = 1.15 to 1.61, P < .001) and OS (pooled HR = 1.27, 95% CI = 1.03 to 1.55, P = .03) and BRAF mutation was also associated with poor DFS (pooled HR = 1.33, 95% CI = 1.00 to 1.78, P = .05) and OS (pooled HR = 1.49, 95% CI = 1.31 to 1.70, P < .001). The effect of the mutations on outcome was enhanced in the MSI-adjusted subgroup for both the KRAS mutation (pooled HR for DFS = 1.43, 95% CI = 1.15 to 1.79, P = .001; and pooled HR for OS = 1.33, 95% CI = 1.03 to 1.71, P = .03) and the BRAF mutation (pooled HR for DFS = 1.59, 95% CI = 1.22 to 2.07, P = .001; and pooled HR for OS = 1.67, 95% CI = 1.37 to 2.04, P < .001). The interaction between BRAF and MSI adjustment was statistically significant for DFS (Pinteraction = .02). This interaction was even more pronounced in the DFS-OS multivariate meta-analysis. CONCLUSIONS: Both KRAS and BRAF mutations were statistically significantly associated with both DFS and OS, with the mutation effect being enhanced by MSI adjustment. Effective adjuvant treatment for microsatellite-stable BRAF or KRAS-mutated colon cancer represents an unmet clinical need, and exploring the use of recently available BRAF and KRAS inhibitors in this setting would be highly desirable.
Authors: Shuji Ogino; Kaori Shima; Jeffrey A Meyerhardt; Nadine J McCleary; Kimmie Ng; Donna Hollis; Leonard B Saltz; Robert J Mayer; Paul Schaefer; Renaud Whittom; Alexander Hantel; Al B Benson; Donna Spiegelman; Richard M Goldberg; Monica M Bertagnolli; Charles S Fuchs Journal: Clin Cancer Res Date: 2011-12-06 Impact factor: 12.531
Authors: George P Kim; Linda H Colangelo; H Samuel Wieand; Soonmyung Paik; Ilan R Kirsch; Norman Wolmark; Carmen J Allegra Journal: J Clin Oncol Date: 2007-01-16 Impact factor: 44.544
Authors: Scott Kopetz; Axel Grothey; Rona Yaeger; Eric Van Cutsem; Jayesh Desai; Takayuki Yoshino; Harpreet Wasan; Fortunato Ciardiello; Fotios Loupakis; Yong Sang Hong; Neeltje Steeghs; Tormod K Guren; Hendrik-Tobias Arkenau; Pilar Garcia-Alfonso; Per Pfeiffer; Sergey Orlov; Sara Lonardi; Elena Elez; Tae-Won Kim; Jan H M Schellens; Christina Guo; Asha Krishnan; Jeroen Dekervel; Van Morris; Aitana Calvo Ferrandiz; L S Tarpgaard; Michael Braun; Ashwin Gollerkeri; Christopher Keir; Kati Maharry; Michael Pickard; Janna Christy-Bittel; Lisa Anderson; Victor Sandor; Josep Tabernero Journal: N Engl J Med Date: 2019-09-30 Impact factor: 91.245
Authors: Patrick G Gavin; Linda H Colangelo; Debora Fumagalli; Noriko Tanaka; Matthew Y Remillard; Greg Yothers; Chungyeul Kim; Yusuke Taniyama; Seung Il Kim; Hyun Joo Choi; Nicole L Blackmon; Corey Lipchik; Nicholas J Petrelli; Michael J O'Connell; Norman Wolmark; Soonmyung Paik; Kay L Pogue-Geile Journal: Clin Cancer Res Date: 2012-10-08 Impact factor: 12.531
Authors: D Arnold; B Lueza; J-Y Douillard; M Peeters; H-J Lenz; A Venook; V Heinemann; E Van Cutsem; J-P Pignon; J Tabernero; A Cervantes; F Ciardiello Journal: Ann Oncol Date: 2017-08-01 Impact factor: 32.976
Authors: Ibrahim Halil Sahin; Subir Goyal; Yoanna Pumpalova; Mohamad B Sonbol; Satya Das; Sigurdis Haraldsdottir; Daniel Ahn; Kristen K Ciombor; Zhengjia Chen; Amber Draper; Jordan Berlin; Tanios Bekaii-Saab; Gregory B Lesinski; Bassel F El-Rayes; Christina Wu Journal: Oncologist Date: 2021-03-22
Authors: David S Hong; Marwan G Fakih; John H Strickler; Jayesh Desai; Gregory A Durm; Geoffrey I Shapiro; Gerald S Falchook; Timothy J Price; Adrian Sacher; Crystal S Denlinger; Yung-Jue Bang; Grace K Dy; John C Krauss; Yasutoshi Kuboki; James C Kuo; Andrew L Coveler; Keunchil Park; Tae Won Kim; Fabrice Barlesi; Pamela N Munster; Suresh S Ramalingam; Timothy F Burns; Funda Meric-Bernstam; Haby Henary; Jude Ngang; Gataree Ngarmchamnanrith; June Kim; Brett E Houk; Jude Canon; J Russell Lipford; Gregory Friberg; Piro Lito; Ramaswamy Govindan; Bob T Li Journal: N Engl J Med Date: 2020-09-20 Impact factor: 176.079
Authors: Yuting Zhang; Zehua Wu; Bin Zhang; Huabin Hu; Jianwei Zhang; Yi Chen; Miaomiao Ding; Yabing Cao; Yanhong Deng Journal: Ann Transl Med Date: 2022-06